A COVID-19 Message from Dr. Rothstein
During the COVID-19 pandemic, Dr. Rothstein is only seeing emergent and urgent patients in person to avoid spread of the coronavirus. Patients who are not urgent can be seen via telemedicine. Patients interested in being evaluated should contact the office at (718) 261-2727; they should leave a message with the receptionist or operator and the office will reach out to them to arrange a meeting with Dr. Rothstein.
On a separate and more important point, Dr. Robert Rothstein and his colleague, Dr. Jonathan Leibowitz discovered an article published in 2006 (Amici C, Di Caro A, Ciucci A, Chiappa L, Castilletti C, Martella V, Decaro N, Buonavoglia C, Capobianchi MR, Santoro MG. Antivir Ther. 2006;11(8):1021-30) which discusses the antiviral properties of indomethacin against the coronavirus which caused the 2002–2004 SARS epidemic. The investigators studied the effect of indomethacin on kidney epithelial cells extracted from an African green monkeys and human lung epithelial cells infected with SARS coronavirus, as well as fibroblasts extracted from dogs infected with canine coronavirus; they found that indomethacin has a potent direct antiviral activity against SARS coronavirus and canine coronavirus by blocking viral RNA synthesis at normally tolerated doses. Additionally, indomethacin was given to orally caninecoronavirus-infected dogs reducing the viral fold by greater than a thousand-fold.
Dr. Leibowitz has begun treating his patients with normally dosed indomethacin with remarkable results. Patients report resolution of coughing and other symptoms one day after beginning the regimen of indomethacin. While these results are preliminary and still anecdotal, Dr. Rothstein and Dr. Leibowitz will continue to monitor the potential this medication has.